Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by bringon10baggeron Jun 07, 2020 10:52am
131 Views
Post# 31121526

RE:SEDAR Report - Clarification

RE:SEDAR Report - Clarificationand besides makes perfect sense to sell after PR rather than sell into expected news, far more negative effect selling in to news and besides everything is on track moving ahead.......sure took some cash out for personal reasons, their business, as noted prior their net share count increased of stayed the same, never know with a few extra bucks they could buy on open market when all weak hands decide to exit........
CaptainPenny wrote: There is nothing to worry about. Sales of shares from executives is planned weeks in advance and they are carried out irregardless of stock price or trading activity. This is to keep them fair from acting on insider info. Dan and John did the same thing last trial, 1-2 weeks after results came out they each sold a rather sizeable chunk of shares. Most executive salaries are comprised of not only cash but a large portion of equity in the company in the form of warrants, RSU's or shares. Its very commonplace for execs to sell large chunks of shares after big events as a way of paying themselves. Management still holds around 20% of the company's shares and are fully vested in the company and would suffer financially, arguably much more so than us, if the stock price was to decline. In addition, I believe most of the management had goal oriented RSU granting for milestone achievements such as successful completion of this trial (if you read the company's annual financial statement there is explicit details of all this).

Think of them selling these as a pre-planned bonus for a trial with positive beneficial results. John and Dan are regular people like the rest of us and probably just want to reward themselves for all the years work


Bullboard Posts